NR4A1 and breast neoplasm: Instead of screening for new drugs targeting genetic or epigenetic alterations in basal-like breast tumors, strategies that induce a switch from hormone receptor-negative to hormone receptor-positive breast tumors could provide established and effective treatment options for a large patient group in need of improved therapy.